LOTTE BIOLOGICS Partners with Ottimo Pharma
LOTTE BIOLOGICS has taken a monumental step in its expansion efforts by signing a significant contract manufacturing agreement with Ottimo Pharma. This collaboration is particularly crucial in the field of antibody therapeutics, where both companies aim to innovate and advance cancer treatments.
Strategic Growth in Antibody Production
The agreement, which is a testament to LOTTE BIOLOGICS' growing reputation as a Contract Development and Manufacturing Organization (CDMO), will enable the production of antibody drug substances at their state-of-the-art facility. Located within the company's Syracuse Bio Campus, this production will support Ottimo Pharma’s promising product, Jankistomig, designed to combat cancer through its unique PD1/VEGFR2 dual pathway mechanism.
Expert Insights
James Park, the CEO of LOTTE BIOLOGICS, expressed enthusiasm about the partnership, stating, "This agreement serves as further validation of our competitiveness as a CDMO in the global antibody therapeutics market. We are committed to not only supplying high-quality medicines that meet global standards but also to adding value for both our partners and patients." This highlights the company’s dedication to quality and resilience in a fast-evolving industry.
Advancements in Manufacturing Capabilities
Joseph Shultz, Vice President of Technical Development and Manufacturing at Ottimo Pharma, remarked on the impact of this collaboration, asserting that it represents a critical milestone in accelerating the development of Jankistomig. He noted, "Partnering with LOTTE BIOLOGICS enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation." This showcases the importance of strategic alliances in the biopharmaceutical sector, emphasizing efficiency and innovation.
LOTTE BIOLOGICS' Broader Vision
LOTTE BIOLOGICS continues to enhance its CDMO services, operating at the Syracuse Bio Campus where services range from cell line development to large-scale contract manufacturing. The company is also gearing up for the operation of Plant 1 at its Songdo Bio Campus, anticipated to begin in the future. This facility is designed to accommodate significant production needs with a capacity of 120,000 liters, facilitating the handling of larger global contracts and reinforcing LOTTE's position in the market.
Global Partnerships and Collaborations
The company has been actively broadening its horizons by forming partnerships with global biopharmaceutical firms across various regions. By leveraging its production capabilities in North America and Asia, LOTTE BIOLOGICS is solidifying its presence in the CDMO space, particularly for antibody therapeutics and Antibody-Drug Conjugates (ADCs). The integration of tailored services through collaborations is setting a new standard in delivering comprehensive and reliable biomanufacturing solutions.
A Customized Approach to Drug Development
Moreover, LOTTE BIOLOGICS has been entering into strategic collaborations with contract development organizations and drug product companies to provide customized end-to-end services. This approach allows them to support clients efficiently from early drug development phases to commercialization, ensuring that each client receives solutions tailored to their specific needs.
About LOTTE BIOLOGICS
Based in Seoul, LOTTE BIOLOGICS was established in 2022 with a resolute mission to deliver transformative therapies vital for a healthier world. The Syracuse Bio Campus is pivotal in their operations, offering advanced GMP manufacturing services for drug substances with a robust capacity of 40,000 liters supported by an array of state-of-the-art bioreactors.
Particularly noteworthy is their venture into Antibody-Drug Conjugates, bolstered by a significant investment aimed at enhancing services related to these modalities. Furthermore, the company is ambitiously constructing three advanced bio plants in Songdo, with the first plant expected to be operational soon, collectively providing a vast production volume exceeding 360,000 liters.
As they move forward, LOTTE BIOLOGICS continues to innovate and adapt, aiming to fulfill the demands of a rapidly changing biopharmaceutical landscape while prioritizing quality and patient outcomes.
Frequently Asked Questions
What is the significance of the contract between LOTTE BIOLOGICS and Ottimo Pharma?
This partnership focuses on the manufacturing of antibody therapeutics, aiming to enhance treatment options for cancer patients.
Where will the antibody drug substances be produced?
The production will take place at LOTTE BIOLOGICS' Syracuse Bio Campus.
What future plans does LOTTE BIOLOGICS have for its facilities?
LOTTE BIOLOGICS plans to operate additional manufacturing facilities at the Songdo Bio Campus to boost production capabilities significantly.
How does LOTTE BIOLOGICS ensure quality in its services?
The company adheres to global standards in manufacturing and has received approvals from over 62 regulatory agencies worldwide.
What is the mission of LOTTE BIOLOGICS?
LOTTE BIOLOGICS is committed to delivering therapies that contribute to a healthier world, focusing on innovation and reliable solutions.
